Medicinal chemistry Study Guide

📖 Core Concepts Medicinal Chemistry – the science that designs, synthesizes, and optimizes small‑molecule drugs (and some biologics) using knowledge of molecular structure and biology. Interdisciplinary Nature – blends organic/biochemistry, computational chemistry, pharmacology, molecular biology, statistics, and physical chemistry. Metallodrugs – therapeutic agents that contain metal ions or metal‑centered complexes (e.g., cisplatin, lithium carbonate, gallium nitrate). Drug Discovery Funnel – Hits → Leads → Optimized Leads → Clinical Candidates → Approved Drug. Hit – a compound that shows desired activity in a primary screen. Lead Optimization – systematic structural changes to improve potency, selectivity, PK/PD, and safety. Lipinski’s Rule of Five – a set of 5 criteria (≤5 H‑bond donors, ≤10 H‑bond acceptors, MW ≤ 500 Da, logP ≤ 5, ≤10 rotatable bonds) that predict good oral bioavailability. Bioisosteres – structural replacements that retain biological activity while modulating physicochemical or metabolic properties. Pharmacophore – the 3‑D arrangement of essential features (e.g., H‑bond donors/acceptors, aromatic rings, cations) required for activity at a target. --- 📌 Must Remember Medicinal Chemistry Goal: turn a hit into a safe, efficacious, marketable drug. Key Metallodrugs: cisplatin (cancer), lithium carbonate (bipolar disorder), gallium nitrate (hypercalcemia). Lipinski Thresholds: H‑bond donors ≤ 5 H‑bond acceptors ≤ 10 Molecular weight ≤ 500 Da logP ≤ 5 Rotatable bonds ≤ 10 Hit Sources: repurposing, natural products, fragment‑based screening, high‑throughput libraries. Lead‑Optimization Priorities: potency, selectivity, metabolic stability, reduced toxicity (genotoxic, hepatic, cardiac). Process Chemistry Focus: scalability, safety, cost, regulatory compliance. Analytical Confirmation: TLC, NMR, GC‑MS verify structure & purity after synthesis. --- 🔄 Key Processes Hit Identification Define biological target. Screen libraries (HTS, fragment‑based, natural products). Confirm activity; discard false positives. Hit‑to‑Lead (Triaging) Evaluate SAR & physicochemical properties. Eliminate compounds lacking favorable SAR or drug‑like metrics. Lead Optimization Iterative synthesis → assay cycle. Modify pharmacophore to improve binding geometry & affinity. Optimize ADME/Tox (e.g., add polar groups for solubility, remove metabolic hotspots). Process Chemistry & Scale‑up Redesign synthetic route for gram‑kilogram scale. Consider reaction thermodynamics, safety, cost, waste. Formulation Development Choose dosage form (tablet, injection, etc.) based on physicochemical profile. Use polymer/solid‑state chemistry to improve stability & release. --- 🔍 Key Comparisons Biologics vs. Small‑Molecule Drugs Biologics: protein/antibody based, administered parenterally, usually do not follow Lipinski rules. Small‑Molecules: low MW, oral bioavailability often assessed by Lipinski. Metallodrugs vs. Organic Drugs Metallodrugs: contain metal center; mechanisms often involve coordination chemistry. Organic Drugs: rely on covalent/non‑covalent interactions of carbon‑based scaffolds. Hits vs. Leads Hits: initial actives, often weak, limited SAR. Leads: refined series with clear SAR, improved potency & drug‑like properties. Fragment‑Based Screening vs. HTS Fragment: low MW fragments (≤ 300 Da), high ligand efficiency, require growing. HTS: large libraries of drug‑like molecules, higher hit rates but lower ligand efficiency. --- ⚠️ Common Misunderstandings “All metallodrugs are toxic.” – Many are safe at therapeutic doses (e.g., lithium). “Lipinski’s rule is absolute.” – Useful guideline; many approved drugs (e.g., cyclosporine) violate one or more criteria. “A hit is automatically a lead.” – Hits often lack sufficient potency or drug‑like properties; extensive triage is required. “Natural products are always superior hits.” – They can be complex, synthetically challenging, and may have poor PK. --- 🧠 Mental Models / Intuition Funnel Analogy: Each stage (hit → lead → candidate) narrows the pool; think of “filtering” by potency, safety, and drug‑likeness. Ligand Efficiency ≈ Activity / Size: Small fragments with modest activity can be more valuable than larger, less efficient molecules. Rule‑of‑Five as a “Speed Bump”: If a molecule fails multiple criteria, expect extra work to improve oral exposure. --- 🚩 Exceptions & Edge Cases Oral Drugs Violating Lipinski: Peptide antibiotics, macrocycles, and some natural products (e.g., cyclosporine). Metallodrugs with Organic Ligands: Some complexes behave like organic drugs (e.g., organometallic anticancer agents). Biologics with Modified Lipophilicity: PEGylation can improve half‑life despite large size. --- 📍 When to Use Which Fragment‑Based vs. HTS: Use fragments when target structure is known and you need high ligand efficiency; use HTS for broader, rapid screening when structural data is limited. Bioisosteric Replacement: Apply when you need to modulate metabolic stability, solubility, or reduce toxicity without losing activity. Process Chemistry Optimization: Initiate once lead series shows promise and you need > 10 g quantities for preclinical studies. Metallodrug Consideration: Choose when the therapeutic mechanism benefits from metal‑mediated redox, DNA binding, or enzyme inhibition (e.g., cancer, mood disorders). --- 👀 Patterns to Recognize Halogen Addition → ↑ Activity & Metabolic Stability (especially Cl, Br). Increasing Polarity → ↑ Solubility but ↓ Membrane Permeability. Rigidifying a Molecule → ↓ Entropic penalty → ↑ binding affinity. Replacing a metabolically labile ester with an amide → ↑ metabolic stability. Presence of multiple aromatic rings → ↑ lipophilicity & possible off‑target binding. --- 🗂️ Exam Traps Distractor: “Lipinski’s rule predicts intravenous drug success.” – Wrong; it predicts oral absorption. Distractor: “All metallodrugs act by releasing free metal ions.” – Many act as intact complexes or via ligand exchange. Distractor: “Hit‑to‑lead is only about improving potency.” – It also screens for drug‑like physicochemical traits. Distractor: “Bioisosteres must be structurally identical.” – They are functional replacements, not identical structures. Distractor: “Process chemistry concerns only yield.” – Safety, cost, waste, and regulatory compliance are equally critical.